// App-Quantinova.ai

: The Novel HDAC Inhibitor Chidamide Synergizes with Rituximab to Inhibit DLBCL Tumor Growth in Vitro and In Vivo By up-Regulating CD20 Expression

Researchers

Presenter

  • Xu-Wen Guan

Principal Investigators

  • Wang Hua-Qing

  • Li Jia

  • Feng-Ting Liu

Medical Centers

  • Department of rheumatology, Tianjin Union Medical Center, Tianjin, China

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Department of rheumatology, Tianjin Union Medical Center, Tianjin, China

Locations

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • B-lymphocyte antigen CD20

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Chidamide

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved